New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RAD;ORCL;NYX;FOLD;GOOG;ELOQ;KMX;ARRS;ICE;MDRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
January 14, 2015
06:29 EDTGOOGCompanies reach new deal on worker hiring issue, Reuters says
Subscribe for More Information
06:14 EDTGOOGMediaTek: Worldwide tablet shipments rise at slower pace, DigiTimes says
Subscribe for More Information
06:03 EDTORCLStocks with implied volatility below IV index mean; ORCL ARNA
Subscribe for More Information
January 13, 2015
13:56 EDTGOOGGM open to partnering with Google on self-driving cars, Time says
GM (GM) would be open to having a discussion with Google (GOOG) about jointly developing self-driving cars, GM Chief Technology Officer Jon Lauckner said, according to Time Magazine. Reference Link
12:32 EDTGOOGGoogle February volatility elevated as shares rally from 14-month low
Google January call option implied volatility is at 21, January weekly is at 22, February is at 28, March is at 23; compared to its 26-week average of 22 according to Track Data, suggesting large near tem price movement.
09:36 EDTGOOGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
06:25 EDTORCLOracle settles legal dispute with Alibaba Health, WSJ reports
Subscribe for More Information
January 12, 2015
13:14 EDTGOOGAnalysts take opposite sides in regards to Google shares
Subscribe for More Information
11:19 EDTGOOGGoogle set to provide real-time translation via Translate app, NY Times reports
Subscribe for More Information
10:23 EDTORCLSAP jumps 3.5% after resuming trade following Q4 report
Subscribe for More Information
10:00 EDTGOOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTGOOGGoogle no longer fixing older Android security flaws, WSJ reports
Subscribe for More Information
09:22 EDTGOOG23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
08:21 EDTGOOGApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:02 EDTGOOGGoogle shares undervalued, says Bernstein
Subscribe for More Information
07:49 EDTFOLDAmicus Therapeutics sees current cash to fund operations into 2017
Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.
07:38 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
07:35 EDTORCLNational Retail Federation to hold a trade show
Subscribe for More Information
06:46 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
06:43 EDTORCLKurian seen by some as successor to Oracle's Ellison, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use